GLP-1 Weight Loss Programs: What Every Med Spa Needs to Know About Medical Director Compliance
Semaglutide and tirzepatide have reshaped med spa weight loss offerings, but they carry higher compliance stakes than most aesthetic services. Here's what medical director oversight actually needs to look like.
GLP-1 Weight Loss Programs: What Every Med Spa Needs to Know About Medical Director Compliance
Semaglutide and tirzepatide have done more to reshape the med spa and wellness clinic industry in the last two years than almost any other single category of treatment. Patient demand is enormous, margins can be strong, and the clinical results speak for themselves. But GLP-1 weight loss programs also come with some of the highest compliance stakes in aesthetic and wellness medicine — and a lot of clinics are moving faster than their oversight structure can support.
If you're offering, or planning to offer, GLP-1 medications like semaglutide or tirzepatide, here's what actually needs to be in place before you scale the program — not after.
Why GLP-1 Programs Carry More Risk Than Most Med Spa Services
Botox and fillers are elective aesthetic procedures with a well-established regulatory framework. GLP-1 weight loss medications are different in a few important ways:
They're prescription medications with real systemic effects. Semaglutide and tirzepatide affect blood sugar regulation, gastric emptying, and appetite signaling throughout the body. Patients with certain thyroid conditions, a history of pancreatitis, or other contraindications need to be properly screened before starting — not after a complication arises.
Compounded versions face active FDA scrutiny. With brand-name GLP-1 medications in periodic short supply, many clinics turned to compounded semaglutide and tirzepatide from 503A and 503B pharmacies. That pathway is legal under the right conditions, but the FDA has been increasingly active in reviewing compounded GLP-1 products, and the rules around when compounding is permitted (shortage status, patient-specific need, sourcing requirements) shift over time. A program built on compounded product needs a medical director and pharmacy partner who are actively tracking that regulatory environment, not relying on what was true a year ago.
Dosing and titration require real clinical judgment. Unlike a standardized injectable protocol, GLP-1 dosing typically escalates over weeks or months based on patient tolerance and response. That's an ongoing clinical relationship, not a one-time treatment — which means ongoing physician oversight, not a single sign-off.
Marketing claims draw regulatory attention. Weight loss is one of the most heavily scrutinized categories in health marketing. Claims about guaranteed results, unrealistic timelines, or off-label uses can create liability that has nothing to do with the medicine itself and everything to do with how it was sold.
What a Compliant GLP-1 Program Actually Looks Like
A medical director with real familiarity with the category. This isn't a service where any signature will do. Your medical director should understand GLP-1 pharmacology, common contraindications, and how to build a protocol that accounts for patient screening, titration schedules, and side effect management — including when a patient needs to be redirected to a physician visit rather than continuing self-administered treatment.
Documented patient screening. A thorough intake — medical history, current medications, relevant labs where appropriate, and a documented conversation about risks and expectations — needs to happen before the first dose, not as an afterthought.
A clear protocol for compounded product, if used. If your program relies on compounded semaglutide or tirzepatide, your medical director and pharmacy partner should be able to clearly explain the legal basis for that sourcing at any given time, since shortage status and FDA guidance can change.
Ongoing monitoring, not a one-time consult. Patients on GLP-1 therapy need scheduled check-ins as doses increase, with a clear process for reporting side effects and a defined point at which the medical director (not just a mid-level provider) gets involved.
Marketing that matches the clinical reality. Results vary by patient, and compliant marketing reflects that. A medical director who's engaged in the business should be reviewing marketing claims around the weight loss program, not just the clinical protocols.
Where Clinics Get This Wrong
Treating GLP-1 like Botox. The biggest mistake we see is clinics applying the same lightweight oversight model they use for injectables to a prescription medication with real systemic risk. A single annual chart review isn't enough for a program where patients are actively titrating doses month over month.
Sourcing compounded product without a compliance-aware pharmacy relationship. Not all compounding pharmacies are equally rigorous about staying current with FDA guidance. A medical director who's paying attention to sourcing — and who has a real relationship with a 503A or 503B pharmacy that takes compliance seriously — is a meaningfully different risk profile than a clinic that's just buying from whoever's cheapest.
Under-resourcing the intake process. GLP-1 programs generate revenue fast, which creates pressure to move patients through intake quickly. Clinics that shortcut screening to increase volume are taking on liability that tends to surface later, not immediately.
No plan for patients who don't respond or have side effects. Every GLP-1 program needs a defined escalation path — what happens when a patient has significant nausea, doesn't lose weight as expected, or reports a symptom that needs physician evaluation rather than just continuing the protocol.
Frequently Asked Questions
Does every state require a physician to prescribe GLP-1 medications directly? Requirements vary. In many states, a nurse practitioner or physician assistant can prescribe under a collaborative or supervisory agreement with a physician, but the specifics — including how closely the physician needs to review each case — differ significantly by state. This is exactly the kind of detail a medical director familiar with your state should already have answered before your program launches.
Is compounded semaglutide or tirzepatide legal? It can be, under specific conditions tied to FDA shortage determinations and patient-specific need, sourced from an appropriately licensed 503A or 503B pharmacy. Because those conditions can change, a program built on compounded product needs ongoing attention from a medical director and pharmacy partner who track FDA guidance closely, rather than a one-time compliance check at launch.
How often should a medical director be involved once a patient starts treatment? More than once. GLP-1 treatment typically involves dose titration over weeks or months, and a defensible program has a documented cadence for physician-level review as doses change or side effects are reported — not just an initial screening.
What's the biggest red flag in an existing GLP-1 program? A medical director who signed the initial paperwork but has no ongoing visibility into patient outcomes, dosing changes, or marketing claims. If nobody can describe what the medical director actually reviews on a recurring basis, that's usually a sign the oversight is nominal rather than real.
Building This the Right Way From the Start
The clinics succeeding long-term with GLP-1 programs aren't the ones who launched fastest — they're the ones who built physician oversight, patient screening, and pharmacy sourcing into the program from day one, rather than retrofitting compliance after a state board inquiry or a patient complaint.
That starts with the medical director relationship. A physician who's genuinely engaged with your GLP-1 program — reviewing protocols, staying current on compounding regulations, and available for the clinical judgment calls that come up as patients progress through treatment — is the single biggest factor in whether a weight loss program is a durable, defensible part of your business or a liability sitting quietly in your patient charts.
If you're building out or scaling a GLP-1 weight loss program and need a medical director who actually understands the category — not just someone willing to sign off on it — that's a conversation worth having before you scale further, not after something goes wrong.